Article Text

PDF
AB0026 B-Cell Profile in RA Patients Treated with Two Different Biological Therapeutic Targets: Anti-TNF and Anti-Il6r. A Cross-Sectional Study
  1. D. Hernández Flόrez,
  2. L. Valor,
  3. I. de la Torre,
  4. T. del Río,
  5. L. Martinez,
  6. E. Naredo,
  7. C. González,
  8. J. Lopez-Longo,
  9. I. Monteagudo,
  10. M. Montoro,
  11. L. Carreño Perez
  1. Rheumatology, Hospital General Universitario Gregorio Marañόn, Madrid, Spain

Abstract

Background B-cells play a cardinal role in the pathogenesis of rheumatoid arthritis (RA) as demonstrated by the effectiveness of B-cell depletion with rituximab (RTX). In the current cross-sectional study, we assessed the phenotypical changes of B-cell subsets in RA patients treated with different anti-cytokine therapeutic targets, anti-TNF: infliximab (IFX), adalimumab (ADA), etanercept (ETA) and the anti-IL6R: tocilizumab (TCZ) compared to healthy controls (HC).

Objectives To evaluate the changes in the B-cell phenotype in RA patients treated with different biological therapeutic agents.

Methods In this cross-sectional study we assessed B-cells expressing BBR (BAFF binding receptors): BAFF-R, TACI, BCMA and the activation marker CD86 in peripheral blood in a total of 108 patients with RA treated with IFX (n=37), ADA (n=28), ETA (n=28) and TCZ (n=14) as well as in HC (n=19). Clinical status of patients was determined using the 28 joints disease activity score (DAS28), defining non-remission as DAS28≥2.6 and remission as DAS28<2.6. Multiparametric flow cytometry was performed using conjugated monoclonal antibodies directed to CD19, CD27, CD38, IgD, BAFF-R, TACI, BCMA and CD86.

Results We found that the frequency of both naïve (CD19+/CD27-)and memory B-cells (CD19+/CD27+) in all RA treatment groups was similar to HC independently of RA disease activity and treatment. Regarding B-cell subsets, in non-remission patients percentages (%) of transitional B cells were higher in TCZ as compared with HC (p=0.03) while memory resting B cells were higher in ADA compared to HC (p=0.01). In patients in remission % of transitional B cells were also higher in TCZ compared with HC (p=0.001) and it was a difference between patients on TCZ and ADA (p=0.002) while memory resting B cells were also higher in ADA compared to HC (p=0.007). Percentages of naïve B-cells expressing BAFF-R and TACI were similar in all groups, while memory B cells expressing TACI were similar to HC only in remission patients on TCZ. About the BCMA expression on memory B-cells, TCZ was similar to HC in non-remission patients. CD86 expression was higher in non-remission patients on TCZ compared to HC (p<0.0001) and as compared with remission patients on TCZ group (p=0.01).

Conclusions Our findings showed a reduced frequency of memory B-cells expressing TACI and BCMA in patients treated with TCZ which might indicate a possible extra regulatory effect on the B-cell phenotype and therefore on the B-cell survival and maturation process, not yet demostrated using anti-TNF-a therapy. These differences migth be a new marker of success or failure for RA therapy.

Disclosure of Interest D. Hernández Flόrez: None declared, L. Valor: None declared, I. de la Torre: None declared, T. del Río: None declared, L. Martinez: None declared, E. Naredo Grant/research support: UCB and MSD, Consultant for: Abbvie, Roche Farma, Bristol-Myers Squibb, Pfizer, UCB, General Electric Healthcare, and Esaote, C. González: None declared, J. Lopez-Longo: None declared, I. Monteagudo Consultant for: Abbvie, Roche Farma, Bristol-Myers Squibb, Pfizer, UCB, General Electric Healthcare, and Esaote, M. Montoro: None declared, L. Carreño Perez: None declared

DOI 10.1136/annrheumdis-2014-eular.3157

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.